Summary
Pfizer Inc. reported total revenues of $11.35 billion for the first quarter of 2014, a decrease of 9% compared to the same period in the prior year, primarily due to the expiration of co-promotion agreements and ongoing generic competition for key products like Lipitor and Viagra. Net income attributable to Pfizer Inc. also saw a decline, down 15% to $2.33 billion, impacted by higher legal charges and the non-recurrence of a gain from a prior-year asset transfer. However, the company maintained a strong financial position with robust operating cash flow and a significant amount of cash and short-term investments. Management highlighted cost-reduction initiatives and growth from newer products like Lyrica and Xeljanz as key drivers, while also facing challenges from patent expirations and an evolving regulatory landscape. The company also noted its ongoing consideration of a potential merger with AstraZeneca. For the quarter, Pfizer's effective tax rate significantly improved to 20.4% from 29.8% in the prior year, largely due to favorable resolutions of prior-year tax positions. This improvement, combined with lower operating expenses from cost-reduction efforts and reduced asset impairment charges, partially offset the decline in revenues and higher legal expenses. The company reaffirmed its previously issued adjusted financial guidance for 2014, indicating confidence in its ability to navigate the current market conditions and deliver on its financial targets.
Financial Highlights
54 data points| Revenue | $11.35B |
| Cost of Revenue | $2.04B |
| Gross Profit | $9.31B |
| SG&A Expenses | $3.04B |
| Operating Income | $2.26B |
| Interest Expense | $321.00M |
| Net Income | $2.33B |
| EPS (Basic) | $0.36 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 6.39B |
| Shares Outstanding (Diluted) | 6.48B |
Key Highlights
- 1Revenues for Q1 2014 decreased by 9% to $11.35 billion, largely impacted by product exclusivity losses and co-promotion agreement expirations.
- 2Net income attributable to Pfizer Inc. declined by 15% to $2.33 billion, impacted by increased legal charges.
- 3The effective tax rate for continuing operations improved significantly to 20.4% from 29.8% in the prior year, driven by favorable tax resolutions.
- 4Lyrica and Xalkori showed strong revenue growth, demonstrating the success of newer products.
- 5Cost of sales, SI&A expenses, and R&D expenses all saw decreases, reflecting cost-management efforts and efficiency gains.
- 6The company's financial position remained strong, with $2.86 billion in cash and cash equivalents and $31.02 billion in short-term investments.
- 7Pfizer is actively considering a potential merger with AstraZeneca, indicating strategic focus on future growth opportunities.